drugset
drugset / Trial / NCT04528667

Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19

NCT04528667 ↗

Phase 2 Completed 396 enrolled Sorrento Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A phase 2, placebo-controlled study of the safety and efficacy of STI-5656 (Abivertinib Maleate) in subjects hospitalized due to COVID-19

Timeline

Start
2021-01-06
Primary completion
2021-08-23
Completion
2021-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Abivertinib Small molecule 100 mg Oral

Indications

COVID-19